Yasutake A, Hirayama K, Inoue M
Biochemistry Section, National Institute for Minamata Disease, Kumamoto, Japan.
Arch Toxicol. 1989;63(6):479-83. doi: 10.1007/BF00316452.
To elucidate the mechanisms by which methyl-mercury (MeHg) is eliminated from organisms, male C57BL/6N mice were orally administered with MeHg chloride (5 mg/kg) and the chemical forms of its metabolites in plasma, urine and kidney were determined by column chromatographic analysis. Orally administered MeHg rapidly entered the circulation, accumulated in the kidney and other tissues, and was slowly excreted in the urine. Ultrafiltration and gel filtration analysis revealed that most of plasma MeHg was accounted for by its albumin conjugate. Cell fractionation analysis revealed that about 80% of renal MeHg was recovered from the 15,000 g supernatant fraction of the kidney homogenate. If the kidney was homogenized in the presence of serine-borate complex, a potent inhibitor of gamma-glutamyltranspeptidase (gamma-GTP), about 50% of the MeHg in the supernatant fraction was recovered as its glutathione S-conjugate while the rest was bound to cytosolic protein(s). The major part of urinary MeHg was accounted for by its cysteine conjugate. However, urinary excretion of its glutathione conjugate increased significantly if animals were pretreated with acivicin, an affinity labeling reagent for gamma-GTP. These and other results suggested that MeHg bound to albumin accumulated in the kidney predominantly via some non-filtrating peritubular mechanism, and localized in renal cytosolic compartment as its glutathione- and protein-bound forms. The glutathione S-conjugate of MeHg in the tubule cells might be transferred to the lumenal space, hydrolyzed to the cysteine S-conjugate, and then excreted in urine. These sequential events might constitute an important eliminatory pathway for a hazardous mercurial metabolite in mice.
为阐明甲基汞(MeHg)从生物体中消除的机制,给雄性C57BL/6N小鼠口服氯化甲基汞(5毫克/千克),并通过柱色谱分析确定其在血浆、尿液和肾脏中代谢产物的化学形式。口服的MeHg迅速进入循环系统,在肾脏和其他组织中蓄积,并缓慢经尿液排出。超滤和凝胶过滤分析表明,血浆中的MeHg大部分以其与白蛋白的结合物形式存在。细胞分级分离分析显示,肾脏中约80%的MeHg可从肾脏匀浆15,000克上清液部分中回收。如果在丝氨酸 - 硼酸盐复合物(γ-谷氨酰转肽酶(γ-GTP)的有效抑制剂)存在的情况下对肾脏进行匀浆,上清液部分中约50%的MeHg以其谷胱甘肽S - 结合物形式回收,其余部分则与胞质蛋白结合。尿中MeHg的主要部分以其半胱氨酸结合物形式存在。然而,如果动物用阿西维辛(一种γ-GTP的亲和标记试剂)预处理,其谷胱甘肽结合物的尿排泄量会显著增加。这些以及其他结果表明,与白蛋白结合的MeHg主要通过某种非滤过性的肾小管周围机制在肾脏中蓄积,并以其谷胱甘肽和蛋白结合形式定位于肾脏胞质区室。肾小管细胞中MeHg的谷胱甘肽S - 结合物可能转移至管腔空间,水解为半胱氨酸S - 结合物,然后经尿液排出。这些连续事件可能构成小鼠体内一种有害汞代谢产物的重要消除途径。